Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nadroparin→

Nadroparin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
~4300 g/mol
Drug class
Low-molecular-weight heparin (LMWH)antithrombin-dependent anticoagulant
Mechanism of action
Binds antithrombin and accelerates inhibition of coagulation factor Xa, with less activity against thrombin (factor IIa) than unfractionated heparin. This reduces fibrin formation and thrombus propagation.
Indications / reported uses
  • Prevention of venous thromboembolism in surgical and medical patients at risk
  • Treatment of deep-vein thrombosis and selected thromboembolic conditions, and use in unstable angina or non-Q-wave myocardial infarction where authorised; product indications vary by jurisdiction

Sources: NLM MeSH — Nadroparin · PubMed — Nadroparin clinical pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nadroparin Environmental Risk Assessment (ERA) (the Nadroparin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.